Microbial Contract Biomanufacturing Market Is Estimated To Be Worth Usd 9.3 Billion In 2030 - Roots

By Author: Kevin Doe
Total Articles: 33
Comment this article

Benefits offered by microbial biomanufacturing, such as low production costs and faster development timelines, have led many innovators to adopt these platforms for next generation biologics, offering lucrative opportunities for CMOs / CDMOs

Roots Analysis is pleased to announce the publication of its recent study, titled, “Microbial Contract Biomanufacturing Market, 2020-2030.

The report features an extensive study of the current market landscape and future opportunities associated with the microbial contract biomanufacturing market. It features a detailed analysis of key drivers and trends related to this evolving domain. In addition to other elements, the study includes:
 A detailed review of the current landscape of companies offering contract manufacturing services.
 Elaborate profiles of key players that specialize in offering services for contract biomanufacturing.
 A competitiveness analysis, highlighting key players engaged in microbial based contract manufacturing, featuring insightful pictorial summaries and representations.
 An analysis of the partnerships and ...
... expansions that have been established in this domain, in the recent past.
 A competitiveness analysis, highlighting key players engaged in microbial based contract manufacturing, featuring insightful pictorial summaries and representations.
 A detailed proprietary 2×2 representation to assess the current market scenario
 An analysis of the initiatives of big biopharma players engaged in this domain.
 A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
 Type of Product
 API
 FDF

 Type of Biologic
 Proteins
 Enzymes
 Growth Hormones
 Antibody based Drugs
 Others (plasmid DNA, probiotics, microbiome-based biologics)

 Type of Microbial Expression System
 Bacteria
 Yeast
 Others (Algae and fungi)

 Scale of Operation
 Commercial
 Preclinical / Clinical

 Type of End User
 Small Companies
 Mid-sized Companies
 Large / Very Large Companies

 Key Geographical Regions
 North America
 Europe
 Asia Pacific
 Middle East and North Africa
 Latin America

Transcripts of interviews held with the following senior level representatives of stakeholder companies
 Gaurav Kaushik (Chief Executive Officer and Managing Director, Meteoric Biopharmaceuticals)
 Debbie Pinkston (Vice President, Sales and Business Development, List Biological Laboratories)
 Andrea Conforto (Sales and Marketing, Bioservices Director, Olon)
 Max Rossetto (General Manager, Business Development, Luina Bio)
 Rob van Dijk (Business Development Manager, WACKER Biotech)

Key companies covered in the report
 AGC Biologics
 Aldevron
 BioVectra
 EirGenix
 Etinpro
 Eurogentec
 Northway Biotechpharma
 Ology Bioservices
 Porton Biopharma
 Stelis Biopharma

For additional details, please visit
https://www.rootsanalysis.com/reports/microbial-contract-biomanufacturing-market.html or email sales@rootsanalysis.com

You may also be interested in the following titles:
1. Drug Repurposing Service Providers Market, 2020 – 2030
2. Antibody Discovery Services and Platforms Market (3rd Edition), 2020-2030
3. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms, 2020 - 2030

Contact:
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Gaurav.Chaudhary@rootsanalysis.com